🔗 Share this article

As the United States undertakes historic changes to its immunization guidelines, one figure has surfaced somewhat surprisingly: Høeg, an American of Danish descent sports medicine doctor and public health researcher who rose to prominence by casting doubt on COVID-19 vaccines during the global health crisis and has focused upon alleged fatalities after Covid immunization in her brief position at the Food and Drug Administration.

Scheduled Overhauls to Pediatric Vaccine Schedule

Agency leaders planned to reveal radical changes to the pediatric immunization program earlier this month, synchronizing the US with Denmark’s national calendar, it is understood – a major change that would place the US out of step with a large portion of the international standard with little proof for public health gain. The planned update has been postponed until the next year.

In place of Vinay Prasad, Tracy Beth Høeg is set to address the audience at the meeting. She was recently named acting director of the FDA’s drug evaluation center, the fifth person to run the center this year.

Consolidating Power at the Regulatory Body

The acting appointment might represent a tighter collaboration between the drug and vaccine centers as Dr. Høeg and Dr. Prasad consolidate power at the regulatory agency – and it suggests a renewed priority upon dismantling previously authorized immunizations at the FDA.

The new acting director has frequently advocated for discontinuing certain pediatric immunization guidelines in the US to become more like the Danish model, a country with nationalized medicine and a citizenry approximately the size of Wisconsin’s.

To date statements, she has kept her attention on immunizations – usually the responsibility of Dr. Prasad, head of the FDA’s CBER – instead of pharmaceutical oversight.

Doubts Over Expertise

The appointee has little discernible track record in pharmaceutical research, oversight or management, which has been typical for previous heads of the CBER. She has served at the FDA as a senior adviser to the commissioner and CBER since March.

“She appears not to have the necessary background” for running the drug-regulation department, stated a neurologist and psychiatrist. “She has not conducted a randomized controlled trial. She is not versed in leading a sizeable institution. She lacks background in drug approvals.”

Past directors of the center would “grasp legal statutes and the science of medication creation”, noted Janet Woodcock. “Frankly, she doesn’t have the sort of resume that prior appointees who ran the center have had.”

The drug center has an immense portfolio at the FDA, she emphasized.

“The public just zeroes in on the new drug program, but the off-patent medication office authorizes numerous generic medications. There’s a biologic copycat branch, non-prescription drug unit and other areas, and every single one need to be looked after,” Woodcock explained. “The responsibility you neglect, that’s the thing that I always told people is going to come back to haunt you.”

Additionally, a major management aspect to the role, which manages more than 5,000 staff members. “It’s a huge management job, if you execute it properly,” she added.

Agency Reaction and Disputed Programs

Regarding concerns about Høeg’s qualifications and whether this appointment indicates more teamwork among regulatory chiefs on vaccines, a spokesperson responded that the “inquiries rely on inaccurate premises”.

“This background is consistent with the functions of her position,” the representative stated, noting the months Dr. Høeg spent advising the FDA commissioner on “medication safety and approval science, including computational safety modeling and vaccine surveillance”.

In her interim role, Dr. Høeg assumes responsibility for the agency head's recently launched priority voucher program, a controversial rapid drug-approval program that apparently troubled her former heads. “By what process are these therapies being selected for this expedited pathway? Who takes the choices?” Dr. Howard said. “There is a lot of lack of transparency occurring at the FDA right now.”

Overall, he said, “the Food and Drug Administration looks to be trending towards less stringent oversight of all drugs, except for shots.”

Public History on Vaccines

Concerning vaccines, Dr. Høeg has a more documented, if concerning, track record, critics said. She released a study using unverified crowd-sourced reports to assess the incidence of heart inflammation following COVID-19 vaccination. She advised the Florida chief medical officer Joseph Ladapo, who was said to have changed statistics to indicate COVID-19 vaccines are riskier than they are.

Part of her “desired changes” for the current government encompassed revising guidelines for new vaccines and ending “optional” immunizations, she remarked after the election on a podcast. At the FDA, Høeg has according to sources suggested excluding teenage boys from getting COVID-19 vaccinations.

“She is an all-around dogmatist who commences with her beliefs and reverse-engineers to accommodate the evidence in a very disingenuous, fraudulent way,” Howard said.

Consolidating Power and a “Push for Payback”

Dr. Høeg became part of fellow skeptics, {like|